Option Care Health (OPCH – Research Report) received a Buy rating and price target from Goldman Sachs analyst Jamie Perse yesterday. The company’s shares closed yesterday at $34.02.
According to TipRanks, Perse is a 3-star analyst with an average return of 3.3% and a 55.17% success rate. Perse covers the Healthcare sector, focusing on stocks such as Agilon Health, Lifestance Health Group, and Option Care Health.
Option Care Health has an analyst consensus of Strong Buy, with a price target consensus of $41.50, representing a 21.99% upside. In a report released on July 28, Barrington also maintained a Buy rating on the stock with a $41.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $35.87 and a one-year low of $24.23. Currently, Option Care Health has an average volume of 3.02M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Option Care Health, Inc. provides home and alternate site infusion services. The company was founded in 1996 and is headquartered in Bannockburn, IL.
Read More on OPCH:
- Option Care Health price target raised to $41 from $34 at Barrington
- Option Care Health sees 2023 revenue $4.2B-$4.3B, consensus $4.3B
- Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2023
- Option Care Health reports Q2 EPS 64c, consensus 22c
- OPCH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
